Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zadavotide guraxetan
- Development stage
- Unknown
- Lead developer
- POINT Biopharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Zadavotide guraxetan is an investigational radioligand therapy consisting of a Prostate-Specific Membrane Antigen (PSMA)-targeting ligand conjugated to the beta-emitting radioisotope lutetium-177. It is designed to deliver targeted radiation directly to cancer cells expressing PSMA, a protein highly overexpressed in prostate cancer and certain other malignancies. Originally developed by Scintomics GmbH and later advanced by Point Biopharma (acquired by Eli Lilly) and Curium, the drug is primarily being evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is currently in Phase 3 clinical development, notably in the ECLIPSE trial, which compares its efficacy and safety against standard-of-care hormonal therapies.
- Other names
- lutetium (177Lu) zadavotide guraxetan177Lu-PSMA-I&T[177Lu]Lu-PSMA-I&TLutetium Lu 177 zadavotide guraxetan
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on zadavotide guraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zadavotide guraxetan.